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Background
The International AIDS Vaccine Initiative (IAVI) has con-
ducted phase I and IIA HIV vaccine clinical trials in
healthy HIV-uninfected African adults. Different recom-
binant DNA and vector-based vaccines encoding HIV-1
genes from subtypes A, B and C were tested. Between 2001
and 2006, 391 volunteers were enrolled in 5 countries at
8 collaborating centers. All vaccines tested were found to
be generally safe and well-tolerated, with no vaccine-
related serious adverse events reported. This study is
designed to monitor any late health effects in prior study
participants.
Methods
At the end of the clinical trial, enrollment into a long-term
follow-up study is offered. Visits are scheduled 6-
monthly. Follow-up is at least 5 years after the last vacci-
nation. A health questionnaire is administered investigat-
ing any health problems, hospitalizations, new diagnoses
of chronic disease, medications prescribed for more than
4 weeks, problems in the vaccinated arm(s), pregnancies
and outcomes, and social harm. HIV testing is performed
to detect incident HIV infection and/or to monitor persist-
ence of vaccine-induced antibodies in HIV-uninfected
volunteers testing HIV positive at final study visit.
Results
So far, 242 individuals have been enrolled in long-term
follow-up. To date, follow up is 301.2 person years. New
diseases lasting over 4 weeks include dermatological (fun-
gal infections), gastrointestinal and musculoskeletal con-
ditions. Seventeen 17 pregnancies, 12 hospitalizations
(mostly pregnancy-related) and 1 new HIV infection have
been reported; 9 volunteers experienced some social
harm. There were no congenital abnormalities. Vaccine
induced antibodies were detected until 2 years and longer
after final study visit.
Conclusion
No significant medical problems have been detected
through long-term follow-up of HIV vaccine study partic-
ipants. Overall, more than 92% of study participants
report to be in good health at any visit. These data contrib-
ute to the long-term safety profile of HIV vaccines tested
in healthy, HIV-negative African adults.
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